How 10x Genomics Could Help Change How Parkinson’s Disease Is Treated – Motley Fool

Related Articles:

• How 10x Genomics Could Help Change How Parkinson's Disease Is Treated - Nasdaq April 6, 2021 How 10x Genomics Could Help Change How Parkinson's Disease Is Treated  Nasdaq
• The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
• The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
• How 10x Genomics Could Help Change How Parkinson's Disease Is Treated April 6, 2021 Genomics ( NASDAQ:TXG) markets technology that is being used to research many diseases. Its platforms are used by researchers across the world. In this video recorded on March 11, 2021, Motley Fool ...
• Parkinson's Disease News - Editor's Picks (Archive 2016.09) October 15, 2016 Newsfeed: PD News PD Research News PD Fitness News PD Boxing News PD Web Articles PD Blogs PD Editor's Picks PD Twitter Newsfeed ‘The Terrorist Inside My Husband’s Brain’: Robin Williams’ Widow Details His Disease – Live ScienceLive Science'The Terrorist Inside My Husband's Brain': Robin Williams' Widow Details His DiseaseLive ScienceBut Robin Williams was not diagnosed with Lewy body disease…
• PPMI RNA-Sequencing, the Largest Dataset of Gene Activity in Parkinson’s, Now Available to Researchers August 27, 2019 The largest dataset ever compiled on Parkinson’s disease research — equivalent to 47.5 billion single-spaced typed pages — is now available to scientists, and can be used to investigate genetic changes over time in people with the neurodegenerative disorder. Funded by the Michael J. Fox Foundation, the “Parkinson’s Progression Markers Initiative (PPMI) RNA-Sequencing Project” can help researchers assess how genetic…
• Progress in Unraveling the Mystery of the Genomics of Parkinson’s Disease January 16, 2020 Since PD was first defined, it has been suspected that there was a genetic component. In June 2009, a small group of investigators met to discuss a potential research alliance focused on the genetics of PD. The outcome was the creation of the IPDGC, a group focused on collaborative genetics research, enabled by trust, sharing, “and as little paperwork as…
• Progress in Unraveling the Mystery of the Genomics of Parkinson’s Disease January 16, 2020 Since PD was first defined, it has been suspected that there was a genetic component. In June 2009, a small group of investigators met to discuss a potential research alliance focused on the genetics of PD. The outcome was the creation of the IPDGC, a group focused on collaborative genetics research, enabled by trust, sharing, “and as little paperwork as…
• Progress in Unraveling the Mystery of the Genomics of Parkinson’s Disease January 16, 2020 Since PD was first defined, it has been suspected that there was a genetic component. In June 2009, a small group of investigators met to discuss a potential research alliance focused on the genetics of PD. The outcome was the creation of the IPDGC, a group focused on collaborative genetics research, enabled by trust, sharing, “and as little paperwork as…
• How Doctors Treat Dementia and Lung Cancer Could Be About to Change - Motley Fool September 18, 2019 How Doctors Treat Dementia and Lung Cancer Could Be About to Change  Motley FoolPatients have new hope following successful trials in dementia-related psychosis and lung cancer treatments.
• Monthy research review – December 2019 December 30, 2019   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• Monthly Research Review – January 2021 January 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during the previous 4 weeks. The post is divided into eight parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical…
• The Neuraly trial November 5, 2019       This week a new clinical trial was registered which caught our attention here at the SoPD HQ. It is being sponsored by a small biotech called Neuraly and involves a drug called NLY01. NLY01 is a GLP-1R agonist – that is a molecule that binds to the Glucagon-like peptide-1 receptor and activates it. Other GLP-1R agonists include…
• 2019: Year in review December 31, 2019   In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2019. Month-by-month we will briefly discuss some of the major pieces of research/announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies to any researchers who…
• These 2 Scrappy Biotechs Could Skyrocket in April - Motley Fool April 4, 2021 These 2 Scrappy Biotechs Could Skyrocket in April  Motley Fool
• 2 Things Investors Are Missing About AbbVie - Motley Fool March 17, 2019 2 Things Investors Are Missing About AbbVie  Motley FoolThe big-pharma company could be in much better shape than you think.
• Does Acadia Pharmaceuticals Have More Room to Run? - Motley Fool September 11, 2019 Does Acadia Pharmaceuticals Have More Room to Run?  Motley FoolAcadia Pharmaceuticals (NASDAQ:ACAD) stock has been on absolute fire in 2019. Thanks to improving sales for its Parkinson's disease psychosis (PDP) ...
• 2 Biotech Takeout Targets Perfect for Biogen - Motley Fool March 23, 2019 2 Biotech Takeout Targets Perfect for Biogen  Motley FoolA midsize acquisition seems imminent, and these two would fit like a glove.
• Why Sorrento Therapeutics Is Jumping Today - Motley Fool April 10, 2019 Why Sorrento Therapeutics Is Jumping Today  Motley FoolGood news from a preclinical study is exciting investors about the potential for one of Sorrento's experimental drugs.
• 3 Biotechs That Have Doubled This Year (Acquisition Next?) - Motley Fool July 2, 2019 3 Biotechs That Have Doubled This Year (Acquisition Next?)  Motley FoolWhen big pharmas go shopping, you usually won't find them sifting through the clearance racks for bargains. For the most part, the large drugmakers would ...
• Is Acadia Pharmaceuticals a Good Biotech Stock to Buy Now? - Motley Fool September 10, 2019 Is Acadia Pharmaceuticals a Good Biotech Stock to Buy Now?  Motley FoolAfter years of dismay, Acadia Pharmaceuticals' (NASDAQ:ACAD) long-term shareholders have a new reason to cheer for the company's only drug, Nuplazid.
• 3 Biotech Stocks That Soared Last Week - The Motley Fool September 15, 2019 3 Biotech Stocks That Soared Last Week  The Motley FoolThe biotech industry's summer doldrums are finally over and a handful of stocks recently posted some big gains for different reasons. Should we expect more ...